Diabetes and Cardiovascular Disease: The Potential Benefit of Incretin-Based Therapies

被引：24
作者：
Addison, Daniel [2 ,3 ]
Aguilar, David [1 ,2 ,3 ]
机构：
[1] Baylor Coll Med, Div Cardiovasc, Houston, TX 77030 USA
[2] Baylor Coll Med, Winters Ctr Heart Failure Res, Houston, TX 77030 USA
[3] Baylor Coll Med, Cardiol Sect, Dept Med, Houston, TX 77030 USA
来源：
CURRENT ATHEROSCLEROSIS REPORTS | 2011年 / 13卷 / 02期
关键词：
Diabetes; Glucagon-like peptide 1; DPP-IV; Incretin hormones; Cardiovascular disease; GLUCAGON-LIKE PEPTIDE-1; MYOCARDIAL GLUCOSE-UPTAKE; GLYCEMIC CONTROL; CARDIAC-FUNCTION; CONSCIOUS DOGS; HEART-FAILURE; MELLITUS; IMPROVES; GLP-1; RISK;
D O I：
10.1007/s11883-010-0153-0
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
The health burden of type 2 diabetes mellitus continues to increase worldwide. A substantial portion of this burden is due to the development of cardiovascular disease in patients with diabetes. Recent failures of clinical trials of intensive glucose control to reduce macrovascular events, coupled with reports of potential harm of certain diabetic therapy, have led to increased scrutiny as new diabetic therapies are developed. Incretin peptides are a group of gastrointestinal proteins that regulate glucose metabolism through multiple mechanisms, and incretin-based therapies have been developed to treat type 2 diabetes. These agents include glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-IV (DPP-IV) inhibitors. In addition to effects on glucose homeostasis, growing evidence suggest that these peptides may also affect the cardiovascular system. In this review, we discuss recent findings concerning the potential, yet untested, benefits of incretin-based pharmacotherapy in the treatment of cardiovascular disease.
引用
收藏
页码：115 / 122
页数：8
相关论文
共 50 条
[1]  
[Anonymous], GUID IND DIAB MELL E
[2]  
[Anonymous], NAT DIAB FACT SHEET
[3]   Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4 [J].
Arakawa, Masayuki ;
Mita, Tomoya ;
Azuma, Kosuke ;
Ebato, Chie ;
Goto, Hiromasa ;
Nomiyama, Takashi ;
Fujitani, Yoshio ;
Hirose, Takahisa ;
Kawamori, Ryuzo ;
Watada, Hirotaka .
DIABETES, 2010, 59 (04) :1030-1037
[4]   Biology of incretins: GLP-1 and GIP [J].
Baggio, Laurie L. ;
Drucker, Daniel J. .
GASTROENTEROLOGY, 2007, 132 (06) :2131-2157
[5]   Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways [J].
Ban, Kiwon ;
Noyan-Ashraf, M. Hossein ;
Hoefer, Judith ;
Bolz, Steffen-Sebastian ;
Drucker, Daniel J. ;
Husain, Mansoor .
CIRCULATION, 2008, 117 (18) :2340-2350
[6]   Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38α MAP Kinase-Mediated, Nitric Oxide-Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy [J].
Bhashyam, Siva ;
Fields, Anjali V. ;
Patterson, Brandy ;
Testani, Jeffrey M. ;
Chen, Li ;
Shen, You-tang ;
Shannon, Richard P. .
CIRCULATION-HEART FAILURE, 2010, 3 (04) :512-521
[7]   Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury [J].
Bose, AK ;
Mocanu, MM ;
Carr, RD ;
Brand, CL ;
Yellon, DM .
DIABETES, 2005, 54 (01) :146-151
[8]   Primary prevention of cardiovascular diseases in people with diabetes mellitus - A scientific statement from the American Heart Association and the American Diabetes Association [J].
Buse, John B. ;
Ginsberg, Henry N. ;
Bakris, George L. ;
Clark, Nathaniel G. ;
Costa, Fernando ;
Eckel, Robert ;
Fonseca, Vivian ;
Gerstein, Hertzel C. ;
Grundy, Scott ;
Nesto, Richard W. ;
Pignone, Michael P. ;
Plutzky, Jorge ;
Porte, Daniel ;
Redberg, Rita ;
Stitzel, Kimberly F. ;
Stone, Neil J. .
CIRCULATION, 2007, 115 (01) :114-126
[9]   Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [J].
Buse, John B. ;
Rosenstock, Julio ;
Sesti, Giorgio ;
Schmidt, Wolfgang E. ;
Montanya, Eduard ;
Brett, Jason H. ;
Zychma, Marcin ;
Blonde, Lawrence .
LANCET, 2009, 374 (9683) :39-47
[10]   Glucagon-like peptide-1 prevents beta cell glucolipotoxicity [J].
Buteau, J ;
El-Assaad, W ;
Rhodes, CJ ;
Rosenberg, L ;
Joly, E ;
Prentki, M .
DIABETOLOGIA, 2004, 47 (05) :806-815
12345